Meeting
2022 ASCO Annual Meeting
Anti-LAG-3 antibody LBL-007 in combination with toripalimab in patients with unresectable or metastatic melanoma: A phase Ⅰ, open-label, multicenter, dose escalation/expansion study.
Authors
Xue Bai
Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, Beijing, China
Xue Bai , Mei Li , Xingxiang Pu , Ying Cheng , Jing Chen , Yu Jiang , Xue Chen , Jingjing Liu , Li Fan , Jun Guo , Lu Si
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT04640545
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9538)
DOI
10.1200/JCO.2022.40.16_suppl.9538
Abstract #
9538
Poster Bd #
131
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
An open-label, single-arm, dose escalation and expansion phase 1 study of tebotelimab (MGD013) plus niraparib in patients with locally advanced or metastatic gastric cancer who failed prior treatments.
First Author: Miaozhen Qiu
First Author: Igor Tsaur
Poster
2023 ASCO Annual Meeting
ALMB-0168, a novel Cx43 hemichannel agonist monoclonal antibody, for metastatic or unresectable osteosarcoma after standard chemotherapy: A multicenter, open-label, single-arm, phase 1 study.
First Author: Jingnan Shen
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Cemiplimab (REGN2810): A fully human anti-PD-1 monoclonal antibody for patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC)—Initial safety and efficacy from expansion cohorts (ECs) of phase I study.
First Author: Kyriakos P Papadopoulos